- WKN: A1K020
- ISIN: DE000A1K0201
- Land: Deutschland
Nachricht vom 20.03.2017 | 17:38
GESCO AG plans cash capital increase
Gesco AG / Key word(s): Capital Increase/Capital Increase
Wuppertal, 20 March 2017 - The Executive Board of GESCO AG, which is listed in the Prime Standard, plans to conduct a cash capital increase out of the authorised capital of up to 10 % of the share capital at the time of the resolution of the Annual General Meeting on the authorised capital subject to the exclusion of the shareholders' subscription rights and to place the up to 864,499 new shares with institutional investors by means of accelerated bookbuilding. The new shares are expected to have full dividend rights for financial year 2016/2017, meaning from 1 April 2016. The Executive Board and Supervisory Board of GESCO AG are expected to adopt a resolution concerning the implementation of the cash capital increase on 21 March 2017 once investors have been contacted.
equinet Bank AG will be acting as sole lead manager and sole bookrunner for the transaction.
The proceeds from the capital increase will be used to further strengthen GESCO AG's equity following the acquisition of the Pickhardt & Gerlach Group, Finnentrop, which took place in January 2017 and broaden the platform for the further internal and external growth of the GESCO Group.
The information contained in this notification is not for publication or transmission in Canada, Australia or Japan and does not constitute an offer of the purchase of securities in these countries.
The issuing of shares and the distribution of this notification and other information connected with the issuing in certain legal systems may be subject to statutory restrictions and anyone finding themselves in possession of documentation cited in this notification or other information should be informed of and observe all such restrictions. Non-observance of these restrictions may constitute a violation of the Securities Trading Act of the legal system concerned.
This notification does not constitute an offer of the purchase of securities in the United States of America. In the United Kingdom, this notification will only be distributed to (i) professional investors categorised as such under Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and (ii) companies and persons of high net worth categorised as such under Article 49(2)(a) to (d) of the Order (such persons are categorised as "qualified persons"). All securities referred to herein are only available to qualified persons and order, offer or agreement regarding the procurement, purchase or other method of acquisition of such securities shall only be entered into with qualified persons. Persons not categorised as qualified persons should never act in respect of or trust in this notification or its content.
This notification does not constitute an offer of the purchase of securities in Germany and is not classified as a sales prospectus under the Securities Prospectus Act, the European Commission directive No. 809/2004 of 29 April 2004 or any other applicable legal provision governing the issue, offer and sale of securities in Germany.
The information contained in this notification is not for transmission in the United States of America or within the United States of America.
Investor Relations, Oliver Vollbrecht
|Phone:||+49 (0)202 248200|
|Fax:||+49 (0)202 2482049|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|
GBC im Fokus
M1 Kliniken AG: Kursziel angehoben
Die M1 Kliniken AG hat den eingeschlagenen Wachstumskurs mit einem Umsatzanstieg von 20,3 % auch im ersten Halbjahr fortgesetzt. Analog dazu gelang es der Gesellschaft, einen überproportionalen Anstieg des EBIT um 36,5% zu erreichen und unsere Erwartungen zu übertreffen. Wir haben auf dieser Grundlage unsere Umsatz- und Ergebnisschätzungen angehoben. Bei einem Kursziel von 16,15 € ergibt sich ein hohes Kurspotenzial - damit lautet das Rating KAUFEN.
Der AKTIONÄR News
20. November 13:57 Egbert Prior: Bei dieser Aktie können Sie früh dabei sein
20. November 13:46 Top-News für Roche: Aktie +5,5% - Kaufsignal in Sicht
20. November 13:32 Schröders Nebenwerte-Watchlist: Meyer Burger, Gesco, Freenet, Tom ...
20. November 13:05 Gold wird nie wieder steigen!
20. November 10:49 Alibaba investiert weitere Milliarden in den Offline-Handel
News im Fokus
ProSiebenSat.1 Media SE: Thomas Ebeling verlässt das Unternehmen Ende Februar 2018
19. November 2017, 19:10
9M RESULTS 2017
15. November 2017
Original-Research: Mologen AG (von First Berlin Equity Research GmbH): BUY
20. November 2017